1[1]Imagawa J,Baxter GF,Yellon DM.Myocardial protection afforded by nicor andil and ischemic preconditioning in a rabbit infarct mode in vivo.J Cardiovas c Pharmacol,1998,31:74～79
2[2]DeMaria AN,Ditttrich H,Kwan OL,et al.Myocardial opacification produced by per ipheral venous injection of a new ultrasonic contrast agent[abstract].Circulat ion,1993,88 Suppl I:401
3[3]Grayburn PA,Erickson JM,Escobar J,et al.Peripheral intravenous myocardial con trast echocardiography using a 2% dodecafluoropentane emulsion:Identification of myocardial risk area and infarct size in the canine model of ischemia.J Am Coll Cardiol,1995,26:1340～1347
4[4]Cole WC,Mxpherson CD,Sontag D.ATP-regulated k+ channels protect the myocar dium against ischemia/reperfusion damage.Circ Res,1991,69:571～581
5[5]Garrett J Gross,John A Auchampach.Blockade of ATP-sensitive potassium channe ls prevents myocardial preconditioning in dogs.Circulation Research,1992,70:223 ～233
6[6]Villanueva FS,Glasheen WP,Sklenar J,et al:Characterization of spatial pattern s of flow within the reperfused myocardium by myocardial contrast echocardiograp hy.implacations in determining extent of myocardial salvage.Circulation,1993,88: 2596～2606
7[7]Villanueva FS,Glasheen WP,Sklenar J,et al.Assessment of risk area during coro nary occlusion and infarct size after reperfussion with myocardial contrast echo cardiography using left atrial and right atrial injections of contrast.Circulati on,1993,88:596～604
8张运，中国超声医学杂志，1999年，15卷，增刊1期，17页
9Porter T R，Am J Cardiol，1998年，82卷，1173页
10Porter T R，J Am Soc Echocardiogr，1999年，12卷，4期，266页
2Paelinck BP, Kasprzak JD. Contrast - enhanced echocardiongraphy: review and current role. Acta Cardiol, 1999,54:195 ～ 201.
3Lindeer JR, Villanueva FS, Dent JM, et al. Assessment of resting perfusion with myocardial contrast echocardiography: theorefcal and practical conciderations. Am Heart J,2000,139(2 Pt 1):231 ～ 240.
4Nagueh SF, Lakkis NM, He ZX, et al. Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol, 1998,32:225 ～ 229.
5Tanaka S, Ioka T, Oshikawa O, et al. Dynamic sonography of hepatic tumors.AJR - Am - J - Roentgenol. 2001,177(4) :799 - 805.
6Blomley M J, Sidhu PS, Cosgrove DO, et al. Do different types of liver lesions differ in their uptake of the microbubble constrast agent SHU 508A in the late liver phase? early exprience. Radiology.2001,220:661 ～ 667.
7Burns PN, Wilson SR, Simpson DH, et al. Pulse inversion imaging of liver blood flow: improved method for characterizing focal masses with microbubble contrast. Invest Radiol, 2000,35: 58 ～ 71.
8Albrecht T, Blomley MJ, Cosgrove DO, et al. Non - invasive diagnosis of hepatic cirrhosis by transis - time analysis of an ultrasound contrast agent.Lancet, 1999,353. (8):1 579～1 583.
9Melany ML, Grant EG, Duerinckx AL, et al. Ability of a phase shift US contrast agent to improve imaging in the main renal arteries. Radiology, 1997;205:147 ～ 152.
10Girard MS, Mattery RF, Baker KG, et al. Comparison of standard and second harmonic B - mode sonography in the detection of segmental renal infarction with sonographic contrast in a rabbit model. J Ultrasound Med, 2000,19 :185～192.
